Literature DB >> 22246386

Predictive value of electrocochleography for determining hearing outcomes in Ménière's disease.

Il Joon Moon1, Ga Young Park, Jeesun Choi, Yang-Sun Cho, Sung Hwa Hong, Won-Ho Chung.   

Abstract

OBJECTIVE: To evaluate the clinical effectiveness of performing electrocochleography (ECoG) at the initial visit in predicting hearing outcomes. STUDY
DESIGN: Retrospective study.
SETTING: Tertiary hospital. PATIENTS: Ninety patients with unilateral, definite Ménière's disease.
INTERVENTIONS: The summating potential (SP)/action potential (AP) ratio was obtained using ECoG at the initial visits. An SP/AP ratio greater than 0.34 was considered abnormal. MAIN OUTCOME MEASURES: Audiogram types, hearing fluctuations, hearing thresholds at the initial and last visits, hearing changes, caloric response, and treatment outcomes were analyzed in subjects with normal and abnormal ECoGs. Correlation analyses between the SP/AP ratio at the initial visit, hearing thresholds at each visit, and hearing changes were performed.
RESULTS: The mean follow-up period was 22.6 months. Abnormal ECoGs were found in 50 (55.6%) of the 90 subjects. No significant differences regarding audiogram types, hearing fluctuations, caloric response, or treatment outcomes were observed between subjects with normal and abnormal ECoGs. Ipsilateral SP/AP ratios at the initial visit were correlated with both hearing thresholds at the initial (r = 0.347, p < 0.001) and last (r = 0.435, p < 0.001) visits. Furthermore, there was a significant correlation between SP/AP ratio and hearing change during follow-up (r = 0.280, p = 0.008). After stratification by initial hearing level, Stage 1 and 2 subjects (hearing threshold, 0-40 dB) with abnormal ECoGs at the initial visit showed a decrease in hearing over time compared with those with normal ECoGs (p = 0.008).
CONCLUSION: A high SP/AP ratio at the initial visit may be used as a predictor of poor hearing outcomes in subjects with Ménière's disease, especially with initial hearing Stage 1 and 2.

Entities:  

Mesh:

Year:  2012        PMID: 22246386     DOI: 10.1097/MAO.0b013e318241b88c

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  7 in total

1.  Clinical Value of Vestibular Evoked Myogenic Potential in Assessing the Stage and Predicting the Hearing Results in Ménière's Disease.

Authors:  Min-Beom Kim; Jeesun Choi; Ga Young Park; Yang-Sun Cho; Sung Hwa Hong; Won-Ho Chung
Journal:  Clin Exp Otorhinolaryngol       Date:  2013-06-14       Impact factor: 3.372

2.  The Role of Mobile Phone Camera Recordings in the Diagnosis of Meniere's Disease and Pathophysiological Implications.

Authors:  Mete Kıroğlu; Muhammed Dağkıran
Journal:  J Int Adv Otol       Date:  2020-04       Impact factor: 1.017

3.  Reappraisal of the glycerol test in patients with suspected Menière's disease.

Authors:  Bernd Lütkenhöner; Türker Basel
Journal:  BMC Ear Nose Throat Disord       Date:  2014-11-24

4.  Usefulness of Intravenous Gadolinium Inner Ear MR Imaging in Diagnosis of Ménière's Disease.

Authors:  Young Sang Cho; Jung Min Ahn; Ji Eun Choi; Hyun Woo Park; Yi-Kyung Kim; Hyung-Jin Kim; Won-Ho Chung
Journal:  Sci Rep       Date:  2018-12-03       Impact factor: 4.379

5.  Pisa Syndrome in Parkinson's Disease: Pathogenic Roles of Verticality Perception Deficits.

Authors:  Young Eun Huh; Kunhyun Kim; Won-Ho Chung; Jinyoung Youn; Seonwoo Kim; Jin Whan Cho
Journal:  Sci Rep       Date:  2018-01-29       Impact factor: 4.379

6.  Factors Contributing to the Severity and Laterality of Pisa Syndrome in Parkinson's Disease.

Authors:  Young Eun Huh; Dae-Won Seo; Kunhyun Kim; Won-Ho Chung; Seonwoo Kim; Jin Whan Cho
Journal:  Front Aging Neurosci       Date:  2022-01-03       Impact factor: 5.750

Review 7.  Electrocochleography for Ménière's disease: is it reliable?

Authors:  Pauliana Lamounier; Débora Aparecida Gobbo; Thiago Silva Almeida de Souza; Carlos Augusto Costa Pires de Oliveira; Fayez Bahmad
Journal:  Braz J Otorhinolaryngol       Date:  2014-08-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.